Correlation Between Apollomics and Reviva Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Apollomics and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apollomics and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Apollomics Class A and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Apollomics and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apollomics with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apollomics and Reviva Pharmaceuticals.

Diversification Opportunities for Apollomics and Reviva Pharmaceuticals

0.39

Correlation Coefficient

Apollomics  Reviva Pharmaceuticals

Weak diversification

The 3 months correlation between Apollomics and Reviva is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Apollomics Class A and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Apollomics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apollomics Class A are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Apollomics i.e., Apollomics and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Apollomics and Reviva Pharmaceuticals

Given the investment horizon of 90 days Apollomics Class A is expected to generate 1.2 times more return on investment than Reviva Pharmaceuticals. However, Apollomics is 1.2 times more volatile than Reviva Pharmaceuticals Holdings. It trades about -0.04 of its potential returns per unit of risk. Reviva Pharmaceuticals Holdings is currently generating about -0.14 per unit of risk. If you would invest  1,013  in Apollomics Class A on December 30, 2024 and sell it today you would lose (252.00) from holding Apollomics Class A or give up 24.88% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Apollomics Class A  vs.  Reviva Pharmaceuticals Holding

Apollomics Class A

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apollomics Class A has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Reviva Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Reviva Pharmaceuticals Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Pair Trading with Apollomics and Reviva Pharmaceuticals

The main advantage of trading using opposite Apollomics and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apollomics position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.

The idea behind Apollomics Class A and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.